Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression

We have previously identified a tyrosine kinase-independent, guanine nucleotide exchange factor (GEF) activity, which is contained within the region of p210 no expansion BCR/ABL that distinguishes it from p190 BCR/ABL. In the current study, we have compared the transforming activity of p190 BCR/ABL, p210 BCR/ABL and a mutant that lacks GEF activity (p210 BCR/ABL(S509A)). In cell-based, ex vivo, and murine bone marrow transplantation (BMT) assays the transforming activity of p210 BCR/ABL(S509A) mimics p190 BCR/ABL, and is distinct from p210 BCR/ABL. Thus, in the BMT assay, the p190 BCR/ABL- and p210 BCR/ABL(S509A)-transplanted mice exhibit a more rapid onset of disease than mice transplanted with p210 BCR/ABL. The reduced disease latency is associated with erythroid hyperplasia in the absence of anemia, and expansion of the megakaryocyte-erythrocyte progenitor (MEP), common myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) populations, producing a phenotype that is similar to acute myeloid leukemia (AML-M6). The disease phenotype is readily transplantable into secondary recipients. This is consistent with ex vivo clonogenicity assays, where p210 BCR/ABL preferentially supports the growth of colony forming unit (CFU)–granulocyte-macrophage (GM), whereas p190 BCR/ABL and the mutant preferentially support the growth of burst forming unit-erythroid (BFU-E). These results suggest that the GEF activity that distinguishes p210 BCR/ABL from p190 BCR/ABL actively regulates disease progression.

• Publication year

  2012

• Venue

  Leukemia

• Publication date

  2012-12-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2012.351PMID 23207522PMCID 3931524
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RhoA of the Rho Family Small GTPases Is Essential for B Lymphocyte Development

  2012cited by this paper
• Chronic myeloid leukemia

  2011cited by this paper
• The function of the pleckstrin homology domain in BCR–ABL-mediated leukemogenesis

  2010cited by this paper
• The small GTPase RhoA is crucial for MC3T3‐E1 osteoblastic cell survival

  2009cited by this paper
• Signaling networks associated with BCR-ABL-dependent transformation.

  2009cited by this paper
• An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.

  2009cited by this paper
• Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs

  2008cited by this paper
• RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek/Erk pathway

  2008cited by this paper
• The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation

  2008influential reference
• Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.

  2007cited by this paper
• Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.

  2007cited by this paper
• The ρ-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34+ CML progenitor cells

  2007cited by this paper
• Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

  2007cited by this paper
• Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover.

  2006cited by this paper
• Survival of Developing Motor Neurons Mediated by Rho GTPase Signaling Pathway through Rho-Kinase

  2004cited by this paper
• RhoA Binds to the Amino Terminus of MEKK1 and Regulates Its Kinase Activity*

  2004cited by this paper
• Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl

  2003cited by this paper
• Critical role for Gab2 in transformation by BCR/ABL.

  2002cited by this paper
• p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.

  2002cited by this paper
• STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.

  2000cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity

  1999influential reference
• Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

  1998cited by this paper
• Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow

  1998cited by this paper
• Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.

  1998cited by this paper
• Dbl family proteins.

  1997cited by this paper
• The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.

  1996cited by this paper
• Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

  1996cited by this paper
• Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells

  1996cited by this paper
• The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

  1996cited by this paper
• The Dimerization Property of Glutathione S-Transferase Partially Reactivates Bcr-Abl Lacking the Oligomerization Domain*

  1996cited by this paper
• A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins

  1993cited by this paper
• BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

  1993cited by this paper
• BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.

  1991cited by this paper
• BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias

  1991cited by this paper
• Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

  1991cited by this paper
• A case of M-BCR-rearranged, Philadelphia-positive AML that relapsed as chronic phase CML [letter]

  1990cited by this paper
• A case of M-BCR-rearranged, Philadelphia-positive AML that relapsed as chronic phase CML.

  1990cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia.

  1988cited by this paper

• RHO subfamily of small GTPases in the development and function of hematopoietic cells

  2024cites this paper
• Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review

  2021cites this paper
• Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.

  2020cites this paper
• Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery

  2019cites this paper
• The adhesion-GPCR BAI1 shapes dendritic arbors via Bcr-mediated RhoA activation causing late growth arrest

  2019cites this paper
• Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.

  2018cites this paper
• RHO GTPases in cancer: known facts, open questions, and therapeutic challenges.

  2018cites this paper
• BCR/ABL analysis in myelodysplastic syndromes

  2018cites this paper
• Dissecting BCR-ABL Variant Signaling Pathways Using Novel Interactome Identification Strategies

  2018cites this paper
• Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis

  2017cites this paper
• Cytogenetic and molecular basis of BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach

  2017cites this paper
• Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase

  2017cites this paper
• Niche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cells

  2017cites this paper
• Effects of ABL SH3-T79Y mutant combined with imatinib on the proliferation of chronic myeloid leukemia cells

  2015cites this paper
• Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia

  2014cites this paper
• AXL kinase as a novel target for cancer therapy

  2014cites this paper
• Function and activation mechanism of PLEKHG2, a novel Gbetagamma-activated RhoGEF in leukemia cells

  2013cites this paper
• Ubiquitin-mediated interaction of p210 BCR/ABL with β-catenin supports disease progression in a murine model for chronic myelogenous leukemia.

  2013cites this paper
• Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity

  2013cites this paper